Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE: HLCM051 in Acute Ischemic Stroke
NCT02961504Phase 3Completed
- Sponsor
- Healios
- Start
- Nov 2017
- Primary completion
- Mar 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing HLCM051 with Placebo (2 arms). Primary endpoints: Proportion of subjects with an excellent outcome defined by the functional assessments at Day 90 and Comparison between the HLCM051 and the placebo groups in key adverse events at Day 90. Started Nov 2017; status: completed.
02
Drugs
invimestrocel
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02961504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961504.